These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27744012)

  • 21. Serum Sclerostin Increases After Acute Physical Activity.
    Pickering ME; Simon M; Sornay-Rendu E; Chikh K; Carlier MC; Raby AL; Szulc P; Confavreux CB
    Calcif Tissue Int; 2017 Aug; 101(2):170-173. PubMed ID: 28374174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology.
    Kemink SA; Hermus AR; Swinkels LM; Lutterman JA; Smals AG
    J Endocrinol Invest; 2000 May; 23(5):295-303. PubMed ID: 10882147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
    Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
    J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men.
    Rucker D; Ezzat S; Diamandi A; Khosravi J; Hanley DA
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):491-9. PubMed ID: 15049965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine.
    Kashii M; Matuso Y; Sugiura T; Fujimori T; Nagamoto Y; Makino T; Kaito T; Ebina K; Iwasaki M; Yoshikawa H
    J Bone Miner Metab; 2016 May; 34(3):315-24. PubMed ID: 26040409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
    Ishimura E; Okuno S; Ichii M; Norimine K; Yamakawa T; Shoji S; Nishizawa Y; Inaba M
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
    Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
    Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the MINOS study.
    Szulc P; Munoz F; Marchand F; Chapuy MC; Delmas PD
    Calcif Tissue Int; 2003 Dec; 73(6):520-30. PubMed ID: 12958693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training.
    Armamento-Villareal R; Sadler C; Napoli N; Shah K; Chode S; Sinacore DR; Qualls C; Villareal DT
    J Bone Miner Res; 2012 May; 27(5):1215-21. PubMed ID: 22392834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating PTH, Vitamin D and IGF-I levels in relation to bone mineral density in elderly women.
    Lumachi F; Camozzi V; Doretto P; Tozzoli R; Basso SM
    In Vivo; 2013; 27(3):415-8. PubMed ID: 23606700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sclerostin in institutionalized elderly women: associations with quantitative bone ultrasound, bone turnover, fractures, and mortality.
    Amrein K; Dobnig H; Wagner D; Piswanger-Sölkner C; Pieber TR; Pilz S; Tomaschitz A; Dimai HP; Fahrleitner-Pammer A
    J Am Geriatr Soc; 2014 Jun; 62(6):1023-9. PubMed ID: 24779429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women.
    Reppe S; Noer A; Grimholt RM; Halldórsson BV; Medina-Gomez C; Gautvik VT; Olstad OK; Berg JP; Datta H; Estrada K; Hofman A; Uitterlinden AG; Rivadeneira F; Lyle R; Collas P; Gautvik KM
    J Bone Miner Res; 2015 Feb; 30(2):249-56. PubMed ID: 25155887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sclerostin quo vadis? - is this a useful long-term mortality parameter in prevalent hemodialysis patients?
    Nowak A; Artunc F; Serra AL; Pollock E; Krayenbühl PA; Müller C; Friedrich B
    Kidney Blood Press Res; 2015; 40(3):266-76. PubMed ID: 25997652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis.
    Morabito N; Catalano A; Gaudio A; Morini E; Bruno LM; Basile G; Tsiantouli E; Bellone F; Agostino RM; Piraino B; La Rosa MA; Salpietro C; Lasco A
    J Bone Miner Metab; 2016 Sep; 34(5):540-6. PubMed ID: 26204844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of bone mineral density and turnover in patients with cystic fibrosis: associations between the IGF system and inflammatory cytokines.
    Street ME; Spaggiari C; Ziveri MA; Volta C; Federico G; Baroncelli GI; Bernasconi S; Saggese G
    Horm Res; 2006; 66(4):162-8. PubMed ID: 16804317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating sclerostin is not suppressed following a single bout of exercise in young men.
    Guerriere KI; Hughes JM; Gaffney-Stomberg E; Staab JS; Matheny RW
    Physiol Rep; 2018 May; 6(10):e13695. PubMed ID: 29845770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
    Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
    J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial.
    Hooshmand S; Brisco JR; Arjmandi BH
    Br J Nutr; 2014 Jul; 112(1):55-60. PubMed ID: 24780728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.